Steven Cohen Travere Therapeutics, Inc. Transaction History

Point72 Asset Management, L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$5.26 - $8.28 $2.9 Million - $4.57 Million	-551,520 Reduced 63.24%	320,580 $2.64 Million
Q1 2024 May 15, 2024	BUY	$7.18 - $9.82 $6.26 Million - $8.56 Million	872,100 New	872,100 $6.72 Million
Q3 2023 Nov 14, 2023	SELL	$7.64 - $17.25 $13.5 Million - $30.6 Million	-1,772,407 Reduced 99.24%	13,572 $121,000
Q2 2023 Aug 14, 2023	BUY	$15.3 - $22.61 $27.3 Million - $40.4 Million	1,785,979 New	1,785,979 $27.4 Million
Q3 2022 Nov 14, 2022	BUY	$22.91 - $28.63 $7.51 Million - $9.38 Million	327,706 New	327,706 $8.08 Million
Q2 2022 Aug 15, 2022	SELL	$20.94 - $30.01 $697,302 - $999,333	-33,300 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$23.61 - $30.6 $786,213 - $1.02 Million	33,300 New	33,300 $858,000
Q2 2021 Aug 16, 2021	SELL	$14.11 - $26.4 $22.7 Million - $42.5 Million	-1,608,126 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$23.37 - $31.77 $23.1 Million - $31.4 Million	987,126 Added 158.96%	1,608,126 $40.2 Million
Q4 2020 Feb 16, 2021	BUY	$19.17 - $27.87 $11.9 Million - $17.3 Million	621,000 New	621,000 $16.9 Million

196

84.9M

776K

900K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.3B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.